JACC:JCSA评分系统对冠脉痉挛性心绞痛患者诊断分层效果良好

2013-09-25 佚名 丁香园

表1:JCSA危险得分与相应MACE发生率 表2:JCSA评分系统的三个危险分层与相应MACE发生率 表3:JCSA评分系统的三个危险分层的MACE发生率曲线 研究要点: 1.此前,已有研究对冠脉痉挛性心绞痛(VSA)患者的临床特征、预后以及诊断因子进行阐明。但若要在临床实践中应用这些诊断相关因子,评估它们在VSA预后中的权重非常重要。 2.为此,研究人员进行此项


表1:JCSA危险得分与相应MACE发生率

表2:jcsa评分系统的三个危险分层与相应mace发生率


表3:JCSA评分系统的三个危险分层的MACE发生率曲线

研究要点:

1.此前,已有研究对冠脉痉挛性心绞痛(VSA)患者的临床特征、预后以及诊断因子进行阐明。但若要在临床实践中应用这些诊断相关因子,评估它们在VSA预后中的权重非常重要。

2.为此,研究人员进行此项研究,旨在为VSA患者的临床预后以及诊断提供评分体系。

3.研究结果表明,JCSA危险度评分可以为VSA患者提供综合危险评估依据并进行诊断分层。

此前,已有一系列研究对冠脉痉挛性心绞痛(VSA)患者的临床特征、预后以及诊断因子进行阐明。但若要在临床实践中应用这些诊断相关因子,评估它们在VSA预后中的权重非常重要。为此,研究人员进行此项研究,旨在为VSA患者的临床预后以及诊断提供评分体系。研究结果表明,JCSA危险度评分可以为VSA患者提供综合危险评估依据并进行诊断分层。文章发表在9月13日JACC在线官网上。【原文下载】

本项研究共纳入1429名VSA患者,其中1276名为回顾性观察数据,153名为前瞻性观察数据。研究中的人口学及临床数据包括:患者年龄、性别,冠脉疾病危险因素,心绞痛类型,阵发性心绞痛发作时患者ST段改变及心律情况,冠脉痉挛激发试验后的影像学表现,药物或机械治疗等。研究的主要终点为主要心血管不良事件(MACE),包括心源性致死,非致死性心梗,因不稳定行心绞痛住院情况、心衰,ICD电击情况等。次要治疗终点是患者全因死亡率。

研究人员建立了多变量Cox比例风险模型,这一模型选取了主要不良心血管事件中的7个预测因子。研究人员根据这些预测因子调整后的风险比对其打分:院外心脏骤停病史(4分),吸烟、静息型心绞痛、器质性冠脉狭窄、多血管痉挛(2分),心绞痛ST抬高、beta受体阻滞剂(1分)。研究人员将患者得分分为3个等级:低危(0-2分),中危(3-5分),高危(>=6分)。

研究结果表明,MACE在低危、中危、高危患者中MACE的发生率分别为2.5%、7.0%、以及13.0%.此外,评分系统也可用于各临床亚组。评分系统在内部测试组和验证组的平均预测率为87.6%和86.5%.研究人员由此得出结论,JCSA危险度评分可以为VSA患者提供综合危险评估依据并进行诊断分层。

研究背景:

冠脉痉挛性心绞痛(VSA)是一种功能性心血管疾病,其临床特征是因冠脉痉挛导致的短暂性心肌缺血。VSA和变异型心绞痛是同义词,这种疾病和很多心血管疾病状况相关,如稳定型心绞痛,急性冠脉综合征以及致死性心力失常等。

此前,已有大量研究表明,VSA患者的基础特征、治疗转归与预后因素可帮助临床医生更好地理解VSA,并可改善医生的临床诊疗。本篇文章的研究人员曾在一项多中心注册研究中发现,院外心脏骤停以及特定的血管造影表现对于VSA具有诊断意义。但是,患者的临床特征以及预后因素在不同的个体间多种多样,且不同的预后因素之间可能存在潜在联系,在临床实践中很难对患者进行危险分层。因此,我们需要一种对VSA患者进行临床诊断的综合评分系统。此前已有一种简单地评分模型可用来评估患者的临床预后,这种模型已用于多种疾病。但是目前对于VSA的诊断和治疗,目前并没有相关的评分系统。

在这项由日本冠脉痉挛协会(JCSA)指导的研究中,研究人员旨在建立一个对VSA患者进行危险分层并预测VSA患者远期不良心血管事件的综合评分系统。

原文下载

Takagi Y, Takahashi J, Yasuda S, Miyata S, Tsunoda R, Ogata Y, Seki A, Sumiyoshi T, Matsui M, Goto T, Tanabe Y, Sueda S, Sato T, Ogawa S, Kubo N, Momomura S, Ogawa H, Shimokawa H; Japanese Coronary Spasm Association.Prognostic stratification of patients with vasospastic angina: a comprehensive clinical risk score developed by the Japanese coronary spasm association.J Am Coll Cardiol. 2013 Sep 24.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2025401, encodeId=3cba202540165, content=<a href='/topic/show?id=395730989d4' target=_blank style='color:#2F92EE;'>#冠脉痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30989, encryptionId=395730989d4, topicName=冠脉痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Thu Aug 28 19:05:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853248, encodeId=fe65185324823, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Apr 11 16:05:00 CST 2014, time=2014-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018342, encodeId=dfc2201834228, content=<a href='/topic/show?id=3b7e3099040' target=_blank style='color:#2F92EE;'>#冠脉痉挛性心绞痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30990, encryptionId=3b7e3099040, topicName=冠脉痉挛性心绞痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Apr 04 20:05:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311727, encodeId=77061311e274b, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Sep 27 00:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324845, encodeId=2c981324845c4, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Sep 27 00:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2025401, encodeId=3cba202540165, content=<a href='/topic/show?id=395730989d4' target=_blank style='color:#2F92EE;'>#冠脉痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30989, encryptionId=395730989d4, topicName=冠脉痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Thu Aug 28 19:05:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853248, encodeId=fe65185324823, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Apr 11 16:05:00 CST 2014, time=2014-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018342, encodeId=dfc2201834228, content=<a href='/topic/show?id=3b7e3099040' target=_blank style='color:#2F92EE;'>#冠脉痉挛性心绞痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30990, encryptionId=3b7e3099040, topicName=冠脉痉挛性心绞痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Apr 04 20:05:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311727, encodeId=77061311e274b, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Sep 27 00:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324845, encodeId=2c981324845c4, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Sep 27 00:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=)]
    2014-04-11 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=2025401, encodeId=3cba202540165, content=<a href='/topic/show?id=395730989d4' target=_blank style='color:#2F92EE;'>#冠脉痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30989, encryptionId=395730989d4, topicName=冠脉痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Thu Aug 28 19:05:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853248, encodeId=fe65185324823, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Apr 11 16:05:00 CST 2014, time=2014-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018342, encodeId=dfc2201834228, content=<a href='/topic/show?id=3b7e3099040' target=_blank style='color:#2F92EE;'>#冠脉痉挛性心绞痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30990, encryptionId=3b7e3099040, topicName=冠脉痉挛性心绞痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Apr 04 20:05:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311727, encodeId=77061311e274b, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Sep 27 00:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324845, encodeId=2c981324845c4, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Sep 27 00:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2025401, encodeId=3cba202540165, content=<a href='/topic/show?id=395730989d4' target=_blank style='color:#2F92EE;'>#冠脉痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30989, encryptionId=395730989d4, topicName=冠脉痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Thu Aug 28 19:05:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853248, encodeId=fe65185324823, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Apr 11 16:05:00 CST 2014, time=2014-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018342, encodeId=dfc2201834228, content=<a href='/topic/show?id=3b7e3099040' target=_blank style='color:#2F92EE;'>#冠脉痉挛性心绞痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30990, encryptionId=3b7e3099040, topicName=冠脉痉挛性心绞痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Apr 04 20:05:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311727, encodeId=77061311e274b, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Sep 27 00:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324845, encodeId=2c981324845c4, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Sep 27 00:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=)]
    2013-09-27 apoenzyme
  5. [GetPortalCommentsPageByObjectIdResponse(id=2025401, encodeId=3cba202540165, content=<a href='/topic/show?id=395730989d4' target=_blank style='color:#2F92EE;'>#冠脉痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30989, encryptionId=395730989d4, topicName=冠脉痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Thu Aug 28 19:05:00 CST 2014, time=2014-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853248, encodeId=fe65185324823, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Apr 11 16:05:00 CST 2014, time=2014-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2018342, encodeId=dfc2201834228, content=<a href='/topic/show?id=3b7e3099040' target=_blank style='color:#2F92EE;'>#冠脉痉挛性心绞痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30990, encryptionId=3b7e3099040, topicName=冠脉痉挛性心绞痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Apr 04 20:05:00 CST 2014, time=2014-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311727, encodeId=77061311e274b, content=<a href='/topic/show?id=624de11204a' target=_blank style='color:#2F92EE;'>#痉挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71120, encryptionId=624de11204a, topicName=痉挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Fri Sep 27 00:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324845, encodeId=2c981324845c4, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Sep 27 00:05:00 CST 2013, time=2013-09-27, status=1, ipAttribution=)]